Prospective Cohort of Locally Advanced and Metastatic Non-Small Cell Lung Cancer Patients With Activating EGFR Mutations
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
274actual
Sites
46
Country
France
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-05-12 | actual | When the study began enrolling |
| Primary completion | 2026-01-15 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-01-15 | estimated | The whole study's end, after follow-up |
| First posted | 2021-11-02 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-12-01 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Non Small Cell Lung Cancer
Intervention
- Drug: Osimertinib — also filed as TAGRISSO
Primary outcome
what the primary-completion date above is the date OFOverall survival
measured 36 months
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed